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Abstract
Background: Viral delivery remains one of the most commonly used techniques today in the field of gene
therapy. However, one of the remaining hurdles is the off-targeting effect of viral delivery. To overcome this
obstacle, we recently developed a method to incorporate an antibody and a fusogenic molecule (FM) as two
distinct molecules into the lentiviral surface. In this report, we expand this strategy to utilize a single chain
antibody (SCAb) for targeted transduction.
Results: Two versions of the SCAb were generated to pair with our various engineered FMs by linking the heavy
chain and the light chain variable domains of the anti-CD20 antibody (aCD20) via a GS linker and fusing them to
the hinge-CH2-CH3 region of human IgG. The resulting protein was fused to either a HLA-A2 transmembrane
domain or a VSVG transmembrane domain for anchoring purpose. Lentiviral vectors generated with either version
of the SCAb and a selected FM were then characterized for binding and fusion activities in CD20-expressing cells.
Conclusion: Certain combinations of the SCAb with various FMs could result in an increase in viral transduction.
This two-molecule lentiviral vector system design allows for parallel optimization of the SCAb and FMs to improve
targeted gene delivery.
Introduction
Gene therapy is the introduction of a functional gene
into a dysfunctional cell for a therapeutic benefit. To
date, viral vectors remain the most commonly used gene
delivery vehicles due to their high transduction efficien-
cies [1,2]. In particular, lentiviral vectors represent one
of the most effective gene delivery vehicles as they allow
for stable long-term transgene expression in both divid-
ing and non-dividing cells. In order to expand the tar-
geted specificity of viral vectors beyond their natural
tropism, numerous studies have been focused on pseu-
dotyping lentiviral vectors with envelope glycoproteins
derived from other viruses, such as the glycoprotein
from vesicular stomatitis virus (VSVG) [3,4]. However,
s i n c et h eV S V Gi st h o u g h tt or e c o g n i z eau b i q u i t o u s
membrane phospholipids instead of a unique cellular
receptor, pseudotyping generates vectors with broad
specificities [5,6]. To mitigate this off-target effect,
previous attempts have been devoted to engineer the
viral glycoprotein to recognize a specific cellular target
by insertion of ligands, peptides, or antibodies [7-16].
Another approach involves bridging the viruses and the
targeted cell with ligand proteins or antibodies [17-20].
However, these modifications to the surface glycoprotein
appear to perturb the natural fusion function of the gly-
coprotein, resulting in a reduction of transduction
efficiency.
Recently, our lab has developed a strategy to target
lentiviral vectors to specific cell types by incorporating a
s u r f a c ea n t i b o d ys p e c i f i ct oC D 2 0a n t i g e na n daf u s o -
genic molecule (FM) as two distinct molecules [21]. Kie-
lian and co-workers reported several versions of the
Sindbis virus glycoprotein that were less dependent on
cholesterol for transduction [22]. We applied these
mutations (E1 226) to the binding defective Sindbis gly-
coprotein and observed that they were able to enhance
transduction efficiency when paired with an anti-CD20
antibody (aCD20) [23]. In this study, we report our
attempt to utilize a single chain antibody (SCAb) to pair
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composed of variable domains of the heavy and light
chains of aCD20, linked by a GS linker and fused to a
hinge-CH2-CH3 region of human IgG. To anchor the
SCAb onto the viral surface, we conjugated the SCAb
with either the HLA-A2 transmembrane domain
(SC2H7-A2) or the VSVG transmembrane domain
(SC2H7-GS). We demonstrated that the lentiviral vector
enveloped with either of these antibody configurations
could achieve targeted transduction to CD20-expressing
cells. We also compared the targeted transduction effi-
ciency and the binding avidity of both versions of the
SCAb and investigate the molecular roles of the dis-
played proteins in mediating lentiviral transduction.
Results
Construction of SCAb for targeting
We have previously demonstrated that targeting lenti-
viral vectors can be generated by co-transfecting produ-
cer cells with a lentiviral vector backbone plasmid,
FUGW, a plasmid encoding an antibody’s heavy and
light chains, a plasmid encoding antibody accessory pro-
teins, and a plasmid encoding a FM, along with lenti-
viral packaging plasmids [21,24]. In this report, we
wanted to expand the targeting strategy by pairing FMs
with SCAbs. To generate the SCAb for this study, we
first PCR-amplified the light chain and heavy chain vari-
able regions of the aC D 2 0a n dl i n k e dt h e mw i t haG S
linker. To allow for the formation of disulfide-linked
dimmers to stabilize the SCAb, the hinge-CH2-CH3
region of the human IgG was fused to the heavy chain
variable region [25-28]. To anchor the SCAb, the HLA-
A2 transmembrane domain or the VSVG transmem-
brane domain was added to the C-terminal and the
resulting constructs were designated as SC2H7-A2 and
SC2H7-GS, respectively (Fig. 1).
Production of lentiviral vectors
We generated SCAb-bearing lentiviral vectors (FUGW/
SC2H7-A2/FM or FUGW/SC2H7-GS/FM) by co-trans-
fecting 293T cells with the lentiviral backbone plasmid
FUGW, a FM-encoding plasmid (SINmu, SGN, SGM, or
AGM), and a plasmid encoding the described SCAb
(pSC2H7-A2, or pSC2H7-GS) along with other neces-
sary packaging plasmids (Fig. 1). Independently, a lenti-
viral vector bearing an isotype control antibody, pAB
and a FM was produced as a non-target control.
Furthermore, we included a VSVG-pseudotyped lenti-
viral vector, FUGW/VSVG as an additional positive con-
trol since VSVG-carrying viral vectors are known to
transduce a variety of different cell types [4]. As shown
in Fig. 2A, FACS analysis of transfected, virus-producing
293T cells showed that virtually all of the cells were
able to be transfected with the viral backbone plasmid
FUGW. Among the GFP-positive cells, roughly 25% to
40% of the producer cells were positive for both the
antibody and the FM (Fig. 2B). As expected, transfection
with VSVG as the envelope protein showed no expres-
s i o no ft h eF Ma n dt h eS C A b .T h es i m i l a rl e v e l so f
transfection and expression of the four FMs suggests
that they could be incorporated into the lentiviral sur-
face with similar efficiency.
Incorporation of SCAb and FM onto lentiviral vectors
A virus-cell binding assay was performed to evaluate
SCAb-mediated binding to CD20-expressing cells. As a
target, we used a 293T cell line stably expressing the
CD20 antigen (designated as 293T/CD20). The parental
cell line 293T served as a negative control. The lentiviral
vector, FUW/SC2H7-A2/SGN or FUW/VSVG, was incu-
bated with either the target cell line, 293T/CD20, or the
control cell line, 293T, for one hour at 4°C, after which,
the cell-virus complex was fixed with 4% formaldehyde
and stained by an anti-p24 antibody to detect the viral
core and 4’,6-diamidino-2-phenylindole (DAPI) for
nucleus. As shown in Fig. 3A, confocal images revealed
that the lentiviral vector (FUW/SC2H7-A2/SGN) was
able to bind to 293T/CD20 cell line, but not to the con-
trol 293T cell line. In contrast, the lentiviral vector
FUW/VSVG was able to bind to both 293T and 293T/
CD20 cell lines. In addition, a quantitative virus-cell
binding assay was conducted to evaluate SCAb-mediated
binding to CD20-expressing cells. Lentiviral vectors
(FUGW/SC2H7-A2/FM, FUGW/SC2H7-GS/FM, and
FUGW/AB/FM) were incubated with either 293T or
293T/CD20 cells for one hour at 4°C to prevent internali-
zation of the viral particle. Cells were then stained for the
presence of viral particles on the cell surface using an
anti-FM antibody and quantified using flow cytometry.
As shown in Fig. 3B, flow cytometry analysis showed that
the vector of either FUGW/SC2H7-A2/FM or FUGW/
SC2H7-GS/FM was able to bind to 293T/CD20 cells.
FACS analysis also showed that the virus bound to the
293T/CD20 cell surface displayed the FMs (Fig. 3B), sug-
gesting that both SCAb and FM were incorporated on
the same virion. Additionally, the control 293T cells
showed no detectable FM, confirming that the observed
viral particle binding to the cells is indeed due to the
SCAb-antigen interaction. Similarly, a non-targeting len-
tiviral vector FUGW/AB/FM was unable to bind to either
293T or 293T/CD20 cells.
Targeted transduction of lentiviral vectors
We conducted transduction experiments to evaluate the
efficiency of lentiviral vectors bearing both SCAb and
FM to transduce the CD20-expressing cell line. The len-
tiviral vector bearing VSVG was used as a positive con-
trol, whereas the lentiviral vector co-displaying AB and
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transduced by indicated lentiviral vectors and analyzed
by FACS five days post-transduction. The GFP expres-
sion level was detected to quantify the specificity and
efficiency.
Recombinant lentiviral vectors bearing both SCAb and
FM were able to specifically transduce the 293T/CD20
cell line with various efficiencies (15% ~ 30%) varying
upon the choice of the FMs (Fig. 4A). In contrast, less
than 5% of transduction efficiency was observed for the
293T cell line. In addition, the titer of FUGW/SC2H7-
A2/SGN was estimated to be ~0.15 × 10
6 transduction
units (TU)/mL on the 293T/CD20 cells (Fig. 4B); the
titer was determined in the dilution ranges that showed
a linear response of GFP expression with viral serial
dilution. In another control experiment, when the lenti-
viral vector bearing an isotype antibody paired with a
FM (FUGW/AB/FM) were used, less than 5% of cells
were transduced to express GFP. This finding further
highlighted the significance of antibody-directed trans-
duction. No transduction was observed with the lenti-
viral vector containing only SCAb, indicating the
necessity of FM to complete transduction. Thus, lenti-
viral vectors must display both SCAb and FM for effi-
cient transduction to target cells.
Among the various lentiviral vectors bearing the same
SCAb but different FMs, different transduction efficien-
cies were observed. The lentiviral vector displaying
SC2H7-A2 and SINmu exhibited 15% transduction effi-
ciency. However, lentiviral vectors displaying other FMs
(SGN, SGM, and AGM) resulted in specific transduc-
tions of 25% to 30%. A similar trend was observed in
another independent study where the SCAb with VSVG
transmembrane domain was used as the targeting anti-
body (SC2H7-GS) (Fig. 4A). In this case, the lentiviral
vector bearing SINmu and SC2H7-GS was able to speci-
fically transduce about 14% of the 293T/CD20 cells,
whereas the specific transduction efficiency was
increased to 25% when other FMs (SGN, SGM and
AGM) were used in combination with the SC2H7-GS.
Assays for studying the entry mechanism
We hypothesized that our engineered lentiviral vector
entered cells via receptor-mediated endocytosis followed
Figure 1 Schematic representation of key constructs in this study. These constructs include a lentiviral backbone vector FUGW, fusogenic
molecule (FM) derived from Sindbis virus glycoprotein, membrane-bound single chain antibody against the CD20 antigen with either a HLA-A2
transmembrane domain (SC2H7-A2) or a VSVG transmembrane domain (SC2H7-GS). CMV enhancer: the enhancer element derived from human
cytomegalovirus; GFP: enhanced green fluorescence protein; Ubi: the human ubiquitin-C promoter; WRE: woodchuck responsive element; CMV:
human cytomegalovirus immediate-early gene promoter; aCD20 V: the variable domain of the kappa chain of the mouse anti-CD20 antibody;
aCD20 Vg: the variable domain of the gamma chain of the mouse anti-CD20 antibody; CH2-CH3 region: the CH2-CH3 region of the human IgG1
antibody; HLA-A2 transmembrane domain: the transmembrane domain of the HLA-A2 protein; VSVG transmembrane domain: the
transmembrane domain of the VSVG protein; E3: the leading peptide of Sindbis virus glycoprotein; E1: the E1 protein of Sindbis virus
glycoprotein for mediating fusion; E2: the E2 protein of Sindbis virus glycoprotein for binding to cellular receptor; HA tag: 10-amino acid epitope
sequence of hemagglutim; pA: polyadenylation signal.
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vector core. To validate our hypothesis, we designed
two independent experiments to study these two critical
steps. Since the combination of SGN and SC2H7-A2
showed the greatest targeting efficiency in the transduc-
tion experiment, we chose this combination for the
study of the entry mechanism. 293T/CD20 cells were
exposed to either FUGW/SC2H7-A2/SGN or FUGW/
VSVG in the presence of various amount of either solu-
ble aCD20 or isotype control antibody (Fig. 5B). As
expected, the level of transduction efficiency (FUGW/
SC2H7-A2/SGN) dropped as the concentration of the
soluble aCD20 increased, whereas no noticeable reduc-
tion in transduction efficiency was observed when the
isotype control was used. In contrast, transduction effi-
ciency of FUGW/VSVG was not affected by soluble
aCD20.
The second critical step of transduction pathway
involved the pH-dependent fusion event leading to the
release of the viral core. To verify the pH requirement,
we incubated either FUGW/SC2H7-A2/SGN or FUGW/
GP160 with 293T/CD20 or Ghost-CCR5 cells in the
increased presence of bafilomycin, which can raise the
pH of the endosomal compartment. We observed a dra-
matic decrease in transduction efficiency (FUGW/
SC2H7-A2/SGN) in response to increasing amount of
bafilomycin (Fig. 5A). In a control experiment where a
pH-independent virus (FUGW/GP160) was used, an
increase in transduction efficiency was observed, which
was consistent with previously published data [29,30].
Thus, the pH in the endosomal compartment is critical
for viral membrane fusion.
pH dependency study on the FMs
As shown from the targeted transduction experiment,
lentiviral vectors enveloped with various FMs resulted in
different targeting efficiency (Fig. 4). We thus designed a
liposome-virus fusion experiment to characterize the
fusion property of these FMs. As shown in Fig. 6,
roughly 40% to 50% of the lentiviral vector (FUGW/
SC2H7-A2/FM) fused at pH of 5.6. When the same
experiment was performed at pH environment of 6.2,
only 12% of the lentiviral vector bearing SINmu fused,
whereas a 40% to 50% fusion activity was obtained for
vectors bearing other FMs (SGN, SGM, and AGM).
Correlating the liposome-virus experiment with the tar-
geted transduction experiment (Fig. 4), we observe a
clear trend showing that the higher fusion activity of the
FMs results in a higher transduction efficiency.
Binding avidity of lentiviral vectors to target cells
In order to understand the different transduction effi-
ciency of lentiviral vectors bearing these two different
versions of SCAb (SC2H7-A2 and SC2H7-GS), we
Figure 2 Co-transfection of virus-producing cells to generate targeting lentiviral vectors. 293T cells were transiently transfected with,
FUGW, pSC2H7-A2, pFM and the other standard packaging plasmids (pMDLg/pRRE and pRSV-Rev) to make FUGW/SC2H7-A2/FM. Antibody
construct pSC2H7-GS was used to generate FUGW/SC2H7-GS/FM. An isotype control antibody construct pAB was used in the transfection to
produce non-targeting lentiviral vector FUGW/AB/FM. Transfection with plasmids encoding VSVG was used to generate a control vector, FUGW/
VSVG. (A) FACS analysis of GFP expression on transfected cells. Solid line, analysis on transfected 293T/CD20 cells; shaded area, analysis on 293T
cells. (B) Analysis of co-expression of the FM and antibody on gated GFP-positive cells. FM was stained using an anti-HA antibody and antibody
was stained using an anti-human IgG antibody.
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the lentiviral vectors (FUGW/SC2H7-A2/SGN and
FUGW/SC2H7-GS/SGN) were incubated with 293T/
CD20 cells followed by the surface staining of the FM.
The geometry mean fluorescence (GMF) intensity was
measured and scatchard analysis was performed to
determine the avidity of the lentiviral vector to bind to
293T/CD20 cells (Fig. 7A). In agreement with our trans-
duction experiment (Fig. 4), the SC2H7-A2-enveloped
lentiviral vector showed slightly better binding avidity to
the target cells as compared to that of the SC2H7-GS-
enveloped lentiviral vector. We also noted that when
SC2H7-A2 was used to envelope the lentiviral vector,
the vector production was increased as compared to
that of SC2H7-GS (Fig. 7B). These findings explain the
result of transduction experiment where the lentiviral
vector pseudotyped with the SC2H7-A2 antibody
showed higher transduction efficiency as compared to
that of SC2H7-GS-bearing vector (Fig. 4).
Discussion
The purpose of this study is to incorporate both mem-
brane-bound SCAb and FM on the lentiviral surface to
achieve targeted transduction to specific cell types.
Previously, we reported a strategy of separating the
binding and fusion functions of viral glycoprotein for
cell specific targeting [21]. By pairing the aCD20 with a
more fusion active FM, the resulted lentiviral vectors
showed enhanced transduction [23]. In this study, we
extended the targeting strategy to utilize a membrane-
bound SCAb with the engineered FMs. Insertion of
SCAb into the viral glycoprotein has shown to be able
to redirect vector particles to specific cellular target
[8,9,13]. However, these modifications usually resulted
in reduced transduction efficiency. Our strategy of
separating binding and fusion functions allows us to
engineer a targeting lentiviral vector system by optimiz-
ing these two parameters in parallel without compro-
mising their functions.
The lentiviral vectors bearing both SCAb and FM can
specifically transduce CD20-expressing cells. The speci-
fic transduction occurs through a two-step process. First
the virus must recognize and bind to CD20-expressing
cells. Using flow cytometry and confocal microscopy, we
verified that the SCAb was able to mediate the binding
of the vector to the CD20 antigen on the cellular sur-
face. Furthermore, the soluble aCD20 inhibition assay
revealed that the targeting kinetics of the SCAb vector
Figure 3 Incorporation of both FM and antibody onto the vector surface. (A) 293T (top) and 293T/CD20 (bottom) cells were incubated
with either FUGW/SC2H7-A2/SGN (left) or FUGW/VSVG (right) at 4°C for 1 hour, fixed and immunostained with anti-p24 antibody (green) and
DAPI nuclear staining (blue). Images were acquired with a laser scanning confocal microscope. Scale bar represents 2 μm. (B) Co-expression of
antibody and FM on the same viral surface. 293T (shaded area) or 293T/CD20 (solid line) cells were incubated with FUGW/SC2H7-A2/FM, FUGW/
SC2H7-GS/FM or FUGW/AB/FM at 4°C for 1 hour, followed by staining of FM by anti-HA antibody. The binding of the virus to the cells was
detected by FACS analysis.
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the binding requirement for the observed targeting. The
second step for targeted transduction is the FM-
mediated endosomal fusion to deliver the viral payload
into the cell. A high titer and efficient transduction
demonstrated that the FM was functional when com-
bined with SCAb on the viral surface. Thus, the target-
ing lentiviral vector succeeds in these two steps to
achieve efficient transduction.
As suggested from our previous studies, two different
approaches can be applied to further optimize this two-
molecule targeting strategy. By engineering the fusion
loop of the SINmu, transduction can be enhanced [23].
Lentiviral vectors incorporating SCAb and SINmu con-
sistently yielded lower transduction efficiency as com-
pared to viral vectors with other FMs (SGN, SGM, or
AGM). The difference in transduction efficiency may
have resulted from the endosomal fusion kinetics of the
different FMs. Recent studies of alphavirus glycoproteins
have indicated that mutation in the E1 fusion domain
might favor an increase in endosomal fusion ability
[31-33]. We suspected that our mutation in the E1
domain might have a similar role in lowering the activa-
tion energy for the fusion event. Our liposome-virus
fusion assay revealed that SINmu was not fusion-active
at pH = 6.2, while other FMs were active at this pH.
This direct correlation between the pH of fusion and
the transduction efficiency suggests that the FMs that
a r em o r ea c t i v ea tah i g h e rp Hc a nh a v eb e t t e rc a p a c i t y
to mediate lentiviral transduction. Consequently, tar-
geted transduction may be further improved by con-
structing a library of FMs and screening for a FM with
higher pH fusion activity.
Another approach to optimize this two-molecule target-
ing strategy is to engineer the targeting antibody to be
more efficiently incorporated onto the lentiviral vector
surface. Having the targeting molecule more efficiently
incorporated onto the vector surface could enhance the
binding of the vector to the cognate receptor on the target
cell surface, thereby increasing transduction efficiency. To
enhance the display of SCAb onto the viral surface, we
constructed two SCAbs, each fused to a different trans-
membrane domain: the HLA-A2 transmembrane domain
or the VSVG transmembrane domain. The targeted trans-
duction efficiency was consistently higher with the
SC2H7-A2-bearing vector. The binding avidity from the
scatchard analysis revealed that the FUGW/SC2H7-A2/
SGN vector exhibited a slightly higher binding avidity as
compared to FUGW/SC2H7-GS/SGN. The higher avidity
of the SC2H7-A2-bearing vector may be due to more
Figure 4 Targeted transduction of lentiviral vectors to 293T/CD20 cells. (A) 293T/CD20 (black bar) or 293T (grey bar) cells were transduced
with 1.5 mL of fresh unconcentrated viral vectors (FUGW/SC2H7-A2/FM, FUGW/SC2H7-GS/FM, FUGW/AB/FM, FUGW/SC2H7-A2, or FUGW/SC2H-
GS). FACS analysis was conducted to analyze the percentage of GFP-expressing cells 5 days post-transduction. (B) Transduction titers of fresh viral
vectors (FUGW/SC2H7-A2/FM, FUGW/SC2H7-GS/FM, or FUGW/VSVG) on 293T (grey bar) and 293T/CD20 (black bar) cells.
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Page 6 of 12Figure 5 Study of the entry mechanism of engineered lentiviral vector for transducing target cells. (A) 293T/CD20 or Ghost-CCR5 cells
were pre-incubated with various amount of bafilomycin for 30 minutes and spin-transduced with FUGW/SC2H7-A2/SGN or FUGW/GP160. Cells
were incubated for an additional 3 hours before replenishing with fresh media. Transduction efficiency was measured by FACS analysis of GFP-
positive cells 3 days post-transduction. All data was normalized to transduction without bafilomycin treatment. (B) Effects of supplement of
soluble aCD20 on targeted transduction. 293T/CD20 cells were incubated with FUGW/SC2H7-A2/SGN or FUGW/VSVG and various amounts of
soluble aCD20 or isotype control for 12 hours, after which the medium was replaced with fresh medium. Transduction efficiency was measured
by FACS analysis of GFP-positive cells 3 days post-transduction. All data was normalized to transduction without soluble antibody treatment.
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vector surface. It has been proposed that lipid rafts can
serve as assembly sites for the pseudotyped lentiviral vec-
tors [34]. Recent studies have demonstrated a correlation
between transmembrane domain and raft association with
efficient viral incorporation [35]. Although these data indi-
cate a role of the transmembrane interaction to facilitate
more efficient incorporation onto the virus, further under-
standing is needed to identify the precise mechanism of




To generate the SCAb against the CD20 antigen, we
first PCR-amplified the light chain variable region from
an aCD20 hybridoma cell line (ATCC, Manassas, VA,
HB-9803) with primers CD20Lvfw (5’-CTG ACC CAG
ACC TGG GCG CAA ATT GTT CTC TCC CAG TCT
CCA GCA ATC CTG TC-3’)a n dC D 2 0 L v G S b w( 5 ’-
CAC CTC CTG AAC CAC CGC CGC TAC CGC CTC
CGC CTT TCA GCT CCA GCT TGG TCC CAG CAC
C-3’). The HLA-A2 leading peptide sequence was then
added to the 5’-end of the light chain variable region
with primers HLA-A2 (5’-GAA CAA TTT GCG CCC
AGG TCT GGG TCA GGG CCA GAG CCC CCG
AGA GTA GCA GGA CGA GGG TTC-3’)a n dH L A -
A2fw (5’-CTT AAG CTT ATG GCC GTC ATG GCG
CCC CGA ACC CTC GTC CTG CTA CTC TCG GGG
G-3’). We also PCR-amplified the heavy chain variable
region with primers CD20hvGSfw (5’-GGT AGC GGC
GGT GGT TCA GGA GGT GGC GGC AGT GGT
GGA GGA TCT CAG GCT TAT CTA CAG CAG TCT
GGG GCT GAG CTG-3’) and CD20hvbw (5’-GTT TTG
TCA CAA GAT TTG GGC TCA ACT GAA GAG
ACG GTG ACC GTG GTC CCT GTG-3’). The PCR
Figure 6 pH-dependent study of the fusion activity of various FMs. R18-labeled lentiviral vectors (FUGW/SC2H7-A2/FM) were mixed with
liposomes (200 μM) for 1 minute. Virus-liposome fusion was triggered by adding the appropriate volume of acetic acid and measured by
dequenching of fluorescent R18 using a spectrofluorometer.
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region using the primers HLA-A2fw and CD20hvbw. To
fuse the hinge-CH2-CH3 domain to the HLA-A2 trans-
membrane domain, we PCR-amplified the hinge-CH2-
CH3 domain and the HLA-A2 transmembrane domain
using the primer pairs (CH2-CH3-Hingefw, 5’-GTC
TCT TCA GTT GAG CCC AAA TCT TGT GAC AAA
ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT
GAA CTC CTG GGG GGA CCG TC-3’; CH2-CH3bw,
5’-CTG GGA AGA CGG GGC CCC CTG TCC GAT
CAT GTT CCT G-3’)a n d( H L A - A 2 T f w ,5 ’-GAC AGG
GGG CCC CGT CTT CCC AGC CCA CCA TCC CC-
3’;H L A - A 2 T b w ,5 ’-CGA GCG GCC GCT CAC ACT
TTA CAA GCT GTG AGA GAC ACA TCA GAG
CCC-3’). The resulting two PCR fragments were
assembled using primers CH2-CH3-Hingefw and HLA-
A2Tbw. We then assembled the variable fragments with
the CH2-CH3/transmembrane domain using the pri-
mers HLA-A2fw and HLA-A2Tbw. The assembled
DNA was finally cloned into pcDNA3 (Invitrogen) via
Hind3 and Not1 restriction sites. To construct a single
chain antibody with the VSVG transmembrane domain,
a forward primer (SC2H7fw, 5’-CCC CCA TCC CGG
GAT GAG CTG ACC-3’) and a backward primer
(SC2H7bw, 5’-AGT ATC ACC GGC CCC CTG TCC
GAT CAT GTT CCT GTA GTC-3’)w e r eu s e dt o
amplify a portion of the CH2-CH3 domain of SC2H7-
A2. In parallel, a forward primer (GSfw, 5’-ATG ATC
GGA CAG GGG GCC GGT GAT ACT GGG CTA
TCC AAA AAT CCA ATC GAG CTT-3’) and a back-
ward primer (GSbw, 5’-GAT CGA GCG GCC GCT
TAC TTT CCA AGT CGG TTC ATC TCT ATG TCT
GTA TAA ATC TGT CTT TTC-3’)w e r eu s e dt o
amplify the transmembrane domain of VSVG. The DNA
products from these two reactions were PCR-assembled
using SC2H7fw and GSbw as the primer pair and the
resulting product was cloned into pSC2H7-A2 to yield
SC2H7-GS. The integrity of these constructs was con-
firmed by DNA sequencing.
Viral vector production
293T cells were seeded in a 6-cm culture dish in
DMEM medium supplemented with fetal bovine serum
(Sigma, St. Louis, MO, 10%), L-glutamine (10 mL/L),
penicillin, and streptomycin (100 units/mL) the night
prior to transfection. 293T cells were transfected at a
confluence of 80~90% with 5 μg of lentiviral backbone
vector (FUGW), 2.5 μg each of pMDLg/pRRE, pRSV-
Rev, pFM, and a plasmid encoding an antibody
(pSC2H7-A2, pSC2H7-GS or pAB) via the standard cal-
cium phosphate precipitation technique [36]. Cells were
replenished with pre-warmed media 4 hours post-trans-
fection. Vectors were harvested two days post-transfec-
tion and filtered through a 0.45-μmp o r es i z ef i l t e r
Figure 7 Scatchard analysis of the lentiviral vector binding to 293T/CD20 cells. (A) 293T/CD20 cells were incubated with various
concentrations of lentiviral vectors (FUGW/SC2H7-A2/SGN or FUGW/SC2H7-GS/SGN) and stained with anti-HA antibody. The apparent Kd value
(1/slope) was derived from the scatchard plot of geometric mean fluorescence (GMF)/concentration versus GMF. (B) p24 concentration of
lentiviral vectors (FUGW/SC2H7-A2/SGN and FUGW/SC2H7-GS/SGN).
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Page 9 of 12(Nalgene, Rochester, NY). Lentiviral vectors were then
further concentrated by ultracentrifugation (Optimal L-
90K Ultracentrifuge, Beckman Coulter, Fullerton, CA) at
4°C, 25,000 rpm for 90 minutes and resuspended in
appropriate volume of cold PBS.
Virus-cell binding assay
293T/CD20 or 293T cells were incubated with 2 mL of
lentiviral vectors (FUGW/SC2H7-A2/FM, FUGW/
SC2H7-GS/FM or FUGW/AB/FM) at 4°C for 1 hour.
After extensive washing with cold PBS, cell-virus com-
plexes were stained with anti-HA tag antibody (Miltenyi
Biotec, Inc.) and analyzed by flow cytometry (FACSort,
BD Bioscience).
Confocal imaging
Fluorescent images were acquired on a Zeiss LSM 510
META laser scanning confocal microscope equipped
with Argon, red HeNe, and green HeNe lasers as well as
a Coherent Chameleon Ti-Sapphire laser for multipho-
ton imaging. Images were acquired using a Plan-apoc-
hromat 63x/1.4 oil immersion objective. To image virus-
cell binding, cells were seeded into a 35-mm glass-bot-
tom culture dish and grown at 37°C overnight. The
seeded cells were rinsed with cold PBS and incubated
with concentrated viral particles for 1 hour at 4°C to
allow for binding. The cells were washed with cold PBS
to remove unbound particles, fixed with 4% formalde-
hyde on ice for 10 minutes, and then immunostained
with monoclonal antibody specific for HIV capsid pro-
tein p24 and 4’,6-diamidino-2-phenylindole (DAPI) anti-
body for nuclear staining. Monoclonal antibody against
H I V - 1p 2 4( A G 3 . 0 )w a so b t a i n e df r o mt h eN I HA I D S
Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH). Images were analyzed using the
Zeiss LSM 510 software version 3.2 SP2.
Antibody Competition Assay
293T/CD20 cells were incubated with the lentiviral vec-
tor (FGUW/SC2H7-A2/SGN or FUGW/VSVG) and var-
ious amount of either the soluble aCD20 (BD
Bioscience) or the isotype control antibody overnight.
Cells were then replenished with fresh media and incu-
bated for additional 72 hours before flow cytometry
analysis.
Neutralization Assay
293T/CD20 or Ghost-CCR5 (NIH AIDS Research and
Reference Reagent Program) cells were pre-incubated
with various amount of bafilomycin for 30 minutes,
after which, the lentiviral vector (FUGW/SC2H7-A2/
SGN or FUGW/GP160) was added. The vector and cell
mixture was spun at 25°C, 2,500 rpm for 90 minutes
using a RT legend centrifuge (Sorval). Cells were then
incubated at 37°C and 5% CO2 and replenished with
fresh media 3 hours later. Flow cytometry was then
used to analyze the treated cells 3 days post-
transduction.
Targeted transduction of 293T/CD20 cells
293T or 293T/CD20 cells were seeded on a 24-well cell
culture plate and spin-trans d u c e dw i t h1 . 5m Lo fi n d i -
cated lentiviral vectors (FUGW/SC2H7-A2/FM, FUGW/
SC2H7-GS/FM, FUGW/AB/FM, FUGW/SC2H7-A2, or
FUGW/SC2H7-GS) at 25°C, 2,500 rpm for 90 minutes
using a RT legend centrifuge. After replacing with fresh
media, the treated cells were cultured for additional 5
days at 37°C and 5% CO2. Flow cytometry was then
used to analyze transduction efficiency. The titer was
determined by measuring GFP-positive cells in the dilu-
tion range that resulted in a linear relationship between
the percentage of GFP-expressing cells and the amount
of vectors added.
Scatchard analysis
293T/CD20 cells were incubated with various amount of
lentiviral vectors (FUGW/SC2H7-A2/SGN or FUGW/
SC2H7-GS/SGN). Flow cytometry analysis was carried
out to measure the geometric mean fluorescence (GMF)
of the bound viruses stained by anti-HA antibody. The
concentration of the lentiviral vectors was measured by
a p24 antigen capture enzyme immunosorbent assay
(ELISA) kit (ImmunoDiagnostics, Woburn, MA). Appar-
ent Kd value was derived from the negative reciprocal of
the slope of the linear fit to scatchard plots, which is the
geometric mean fluorescence/concentration of lentiviral





were purchased from Avanti Polar Lipids (Alabaster,
AL, USA). Cholesterol (Chol) and sphingomyelin (SPM)
from egg yolk were obtained from Sigma (St Louis, MO,
USA). Liposomes were prepared by the extrusion proce-
dure [37]. Briefly, lipid mixtures (PC/PE/SPM/Chol
molar ratio of 1:1:1:2) were dried from a chloroform
solution under a stream of argon gas and further dried
under vacuum for at least 3 hours. The lipid mixtures
were hydrated in HNE buffer (5 mM HEPES, 150 mM
NaCl, and 0.1 mM EDTA, pH 7.4). Subsequently, the
lipid mixtures were extruded 20 times through 0.2 μm
pore size polycarbonate filters (Avanti polar lipids). To
monitor virus-liposome fusion, the concentrated viruses
were incubated with 70 μM of octadecyl rhodamine B
chloride (R18) (Molecular Probes, Carlsbad, CA, USA)
in serum-free medium for 1 hour at room temperature.
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Page 10 of 12R18-labeled viruses were then mixed with liposomes
(200 μM phospholipids) in a final volume of 0.4 mL.
Fusion was triggered by adding the appropriate volume
of 0.2 M acetic acid, pretitrated to achieve the desired
pH. The dequenching signal of R18 fluorescence was
measured 60 seconds after acidification with Quanta-
Master QM-4SE spectrofluorometer (Photon Technol-
ogy International, Lawrenceville, NJ, USA). The initial
fluorescence of virus-liposome mixtures was set at 0%
fusion, and the 100% fusion value was obtained by
detergent lysis for each experiment using 0.1% of Triton
X-100 [38].
Authors’ contributions
YL and PW designed research; YL, KJ, JZ and CW performed research; YL and
PW analyzed data and wrote the paper. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2009
Accepted: 11 February 2010 Published: 11 February 2010
References
1. Verma I, Somia. N: Gene therapy - promises, problems and prospects.
Nature 1997, 389:239-242.
2. Verma I, Weitzman M: Gene therapy: twenty-first century medicine. Annu
Rev Biochem 2005, 74:711-738.
3. Burns J, Friedmann T, Driever W, Burrascano M, Yee J: Vesicular stomatitis
virus G glycoprotein pseudotyped retroviral vectors: concentration to
very high titer and efficient gene transfer into mammalian and
nonmammalian cells. Proc Nat Acad Sci USA 1993, 90:8033-8037.
4. Cronin J, Zhang X, Reiser J: Altering the tropism of lentiviral vectors
through pseudotyping. Curr Gene Ther 2005, 5:387-398.
5. Mastromarino P, Conti C, Goldoni P, Hauttecoeur B, Orsi N: Characterization
of membrane components of the erythrocyte involved in vesicular
stomatitis virus attachment and fusion at acidic pH. J Gen Virol 1987,
68:2359-2369.
6. Hall M, Burson K, Huestis W: Interactions of a vesicular stomatitis virus G
protein fragment with phosphatidylserine: NMR and fluorescence
studies. Biochim Biophys Acta 1998, 1415:101-113.
7. Nguyen T, Pages JC, Farge D, Briand P, Weber A: Amphotropic retroviral
vectors displaying hepatocyte growth factor-envelope fusion proteins
improve transduction eficiency of primary hepatocytes. Hum Gene Ther
1998, 17:2469-2474.
8. Somia N, Zoppe M, Verma I: Generation of targeted retroviral vectors by
using single-chain variable fragment: an approach to in vivo gene
delivery. Proc Nat Acad Sci USA 1995, 92:7570-7574.
9. Jiang A, Dornburg R: In vivo cell type-specific gene delivery with
retroviral vectors that display single chain antibodies. Gene Ther 1999,
6:1982-1987.
10. Martin F, Chowdhury S, Neil S, Phillipps N, Collins MK: Envelope-targeted
retrovirus vectors transduce melanoma xenografts but not sleen or liver.
Mol Ther 2002, 5:269-274.
11. Valsesia-Wittmann S, Drynda A, Deleage G, Aumailley M, Heard J, Danos O,
Verdier G, Cosset F: Modifications in the binding domain of avian
retrovirus envelope protein to redirect the host range of retroviral
vectors. J Virol 1994, 68:4609-4619.
12. Kasahara N, Dozy A, Kan Y: Tissu-specific targeting of retroviral vectors
through ligand-receptor interactions. Science 1994, 266:1373-1376.
13. Jiang A, Chu T, Nocken F, Cichutek K, Dornburg. R: Cell type-specific gene
transfer into human cells with retroviral vectors that display single chain
antibodies. J Virol 1998, 72:10148-10156.
14. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL: Efficient
gene transfer into human primary blood lymphocytes by surface-
engineered lentiviral vectors that display a T cell-activating polypeptide.
Blood 2002, 99:2342-2350.
15. Fielding AK, Fernandes SC, Chadwick MP, Bullough FJ, Cosset FL: A
Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting
of a Cytotoxic Gene by Ligand Display. Hum Gene Ther 2000, 11:817-826.
16. Gollan TJ, Green MR: Selective targeting and inducible destruction of
human cancer cells by retroviruses with envelope proteins bearing short
peptide ligands. J Virol 2002, 76:3564-3569.
17. Morizono K, Bristol G, Xie Y, Kung S, Chen I: Antibody-directed targeting
of retroviral vectors via cell surface antigens. J Virol 2001, 75:8016-8020.
18. Morizono K, Xie Y, Ringpis G, Johnson M, Nassanian H, Lee B, Wu L,
Chen ISY: Lentiviral vector retargeting to P-glycoprotein on metastatic
melanoma through intravenous injection. Nat Med 2005, 11:346-352.
19. Roux P, Jeanteur P, Piechaczyk M: A versatile and potentially general
approach to the targeting of specific cell types by retroviruses:
application to the infection of human cells by means of major
histocompatibility complex class I and class II antigens by mouse
esctropic murine leukemia virus-derived viruses. Proc Nat Acad Sci USA
1989, 86:9079-9083.
20. Boerger A, Snitkovsky S, Young J: Retroviral vectors preloaded with a viral
receptor-ligand bridge protein are targeted to specific cell types. Proc
Nat Acad Sci USA 1999, 96:9867-9872.
21. Yang L, Bailey L, Baltimore D, Wang P: Targeting lentiviral vectors to
specific cell types in vivo. Proc Nat Acad Sci USA 2006, 103:11479-11484.
22. Lu L, Cassese T, Kielian M: The Chloesterol Requirement for Sindbis Virus
Entry and Exit and Characterization of a Spike Protein Region Involved
in Cholesterol Dependence. J Virol 1999, 73:4272-4278.
23. Lei Y, Joo KI, Wang P: Engineering fusogenic molecules to achieve
targeted transduction of enveloped lentiviral vectors. J Biol Eng 2009, 3:8.
24. Yang H, Zeigler L, Joo K-I, Cho T, Lei Y, Wang P: Gamma-retroviral vectors
enveloped with an antibody and an engineered fusogenic protein
achieved antigen-specific targeting. Biotechnol Bioeng 2008, 101:357-368.
25. Liao K, Chou W, Lo Y, Roffler S: Design of transgenes for efficient
expression of active chimeric proteins on mammalian cells. Biotechnol
Bioeng 2000, 73:313-323.
26. Chou W, Liao K, Lo Y, Jiang S, Yeh M, Roffler S: Expression of chimeric
monomer and dimer proteins on the plasma membrane of mammalian
cells. Biotechnol Bioeng 1999, 65:160-169.
27. Liao K, Chen B, Liu T, Tzou S, Lin Y, Lin K, Su C, Roffler S: Stable expression
of chimeric anti-CD3 receptors on mammalian cells for stimulation of
antitumor immunity. Cancer Gene Ther 2003, 10(10):779-90.
28. Roffler S, Wang H, Yu H, Chang W, Cheng C, Lu Y, Chen B, Cheng T: A
membrane antibody receptor for noninvasive imaging of gene
expression. Gene Ther 2006, 13:412-420.
29. Fredericksen B, Wei B, Yao J, Luo T, Garcia J: Inhibition of endosomal/
lysosomal degradation increases the infectivity of human
immunodeficiency virus. J Virol 2002, 76:11440-11446.
30. McClure M, Marsh M, Weiss R: Human immunodeficiency virus infection
of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J
1988, 7:513-518.
31. Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, Lepault J, Kielan M,
Rey FA: Conformational change and protein-protein interactions of the
fusion protein of Semliki Forest virus. Nature 2004, 427:320-325.
32. Kielian M, Rey FA: virus memrane-fusion proteins: more than one way to
make a hairpin. Nat Rev Microbiol 2006, 4:67-76.
33. Liu CY, Kielian M: E1 mutants identify a critical region in the trimer
interface of the semliki forest virus fusion protein. J Virol 2009,
83(21):11298-11306.
34. Leung K, Kim JO, Ganesh L, Kabat J, Schwartz O, Nabel GJ: HIV-1 assembly:
viral glycoproteins segregate quantally to lipid rafts that associate
individually with virions. Cell Host Microbe 2008, 3:285-292.
35. Jorgenson RL, Vogt VM, Johnson MC: Foreign glycoproteins can be
actively recruited to virus assembly sites during pseudotyping. J Virol
2009, 83:4060-4067.
36. Klages N, Zufferey R, Trono D: A stable system for the high-titer
production of multiply attenuated lentiviral vectors. Mol Ther 2000,
2:170-176.
37. Smit JM, Bittman R, Wilschut J: Low-pH-dependent fusion of sindvis virus
with receptor-free cholesterol- and sphingolipid-containing liposomes. J
Virol 1999, 73:8476-8484.
Lei et al. Virology Journal 2010, 7:35
http://www.virologyj.com/content/7/1/35
Page 11 of 1238. Wunderli-Allenspach H, Ott S: Kinetics of fusion and lipid transfer
between virus receptor containing liposomes and influenza viruses as
measured with the octadecylrhodamine B chloride assay. Biochemistry
1990, 29:1990-1997.
doi:10.1186/1743-422X-7-35
Cite this article as: Lei et al.: Targeting lentiviral vector to specific cell
types through surface displayed single chain antibody and fusogenic
molecule. Virology Journal 2010 7:35.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lei et al. Virology Journal 2010, 7:35
http://www.virologyj.com/content/7/1/35
Page 12 of 12